2025 Q3 -tulosraportti
Vain PDF
78 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
35
Myynti
Määrä
1 517
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 | - | - | ||
| 3 | - | - | ||
| 1 | - | - | ||
| 1 | - | - | ||
| 1 | - | - |
Ylin
6,56VWAP
Alin
6,315VaihtoMäärä
3,5 539 615
VWAP
Ylin
6,56Alin
6,315VaihtoMäärä
3,5 539 615
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·15 t sittenI am completely convinced that we will see 5:- before Q1 is over, unfortunately.
·11 t sittenI bet against and say that we will touch 8 kr before Q1 ends - based on readout of CU/ EAP 🤞🏽·9 t sittenI hope you are right, but my assessment is that we might see price levels around 5 kr before data is presented. Uncertainty is high and there is clear selling pressure from actors who want to exit their positions regardless of price, which continues to push the price down. After the data is released, it is impossible to predict the outcome. If the result is positive, I can definitely see levels around 8 kr or higher, but until then, the price is driven more by sentiment than fundamentals. It is also noticeable in forums and Discord that many are trying to support each other, but unfortunately, the price development has been negative for a longer period, which is frustrating for all investors, including myself. I still hope that the company delivers strong data going forward and that the trend turns in the long run.
·8.2.Advancement for Cereno Scientific and candidate CS1 The Expanded Access Program (EAP) has now concluded after the last patient completed their last visit. This provides the company with access to valuable long-term data that complements the promising signals of "reverse vascular remodeling" observed in phase IIa. The insights from the EAP will now pave the way for the next major development step: a global phase IIb study with planned recruitment start in Q2 2026. 💬 – Reaching last patient last visit in the EAP is an important milestone, says CEO Sten R. Sörensen.- ·5.2.Very good KMD today from management. The future looks bright, I am convinced of that. The only question is how long the market will delay reflecting the value in the share price. For those who are long-term, this will definitely pay off over time. Now we are just over +5 %, but if you know Cereno, you know that it often swings quickly and one should not be surprised if we are down again short-term. At the same time, that doesn't fundamentally change the case. The company continues to deliver, and sooner or later fundamentals usually catch up with the valuation.
·6.2.They value Cereno at 6.6 billion at the start of Phase 2b. The market for PAH is far from as large as, for example, for oncological studies which are valued in the same range. As Sten says, we hope that if all goes well, we will have a product on the market in 5-6 years. When Merck acquired winrevair, Sotatercept was in Phase 3. But yes, I have shares, will hold the shares all the way, but that we are approaching 21 SEK per share this year, I have great doubts about. But I'll be the first to admit if I'm wrong 👌 
·3.2.Many nervous souls here which makes the stock fall. Waiting for the market day February 5 with news and possible investors who will pull the stock in the right direction. See enormous potential here👍🚀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
78 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·15 t sittenI am completely convinced that we will see 5:- before Q1 is over, unfortunately.·11 t sittenI bet against and say that we will touch 8 kr before Q1 ends - based on readout of CU/ EAP 🤞🏽·9 t sittenI hope you are right, but my assessment is that we might see price levels around 5 kr before data is presented. Uncertainty is high and there is clear selling pressure from actors who want to exit their positions regardless of price, which continues to push the price down. After the data is released, it is impossible to predict the outcome. If the result is positive, I can definitely see levels around 8 kr or higher, but until then, the price is driven more by sentiment than fundamentals. It is also noticeable in forums and Discord that many are trying to support each other, but unfortunately, the price development has been negative for a longer period, which is frustrating for all investors, including myself. I still hope that the company delivers strong data going forward and that the trend turns in the long run.
- ·8.2.Advancement for Cereno Scientific and candidate CS1 The Expanded Access Program (EAP) has now concluded after the last patient completed their last visit. This provides the company with access to valuable long-term data that complements the promising signals of "reverse vascular remodeling" observed in phase IIa. The insights from the EAP will now pave the way for the next major development step: a global phase IIb study with planned recruitment start in Q2 2026. 💬 – Reaching last patient last visit in the EAP is an important milestone, says CEO Sten R. Sörensen.
- ·5.2.Very good KMD today from management. The future looks bright, I am convinced of that. The only question is how long the market will delay reflecting the value in the share price. For those who are long-term, this will definitely pay off over time. Now we are just over +5 %, but if you know Cereno, you know that it often swings quickly and one should not be surprised if we are down again short-term. At the same time, that doesn't fundamentally change the case. The company continues to deliver, and sooner or later fundamentals usually catch up with the valuation.·6.2.They value Cereno at 6.6 billion at the start of Phase 2b. The market for PAH is far from as large as, for example, for oncological studies which are valued in the same range. As Sten says, we hope that if all goes well, we will have a product on the market in 5-6 years. When Merck acquired winrevair, Sotatercept was in Phase 3. But yes, I have shares, will hold the shares all the way, but that we are approaching 21 SEK per share this year, I have great doubts about. But I'll be the first to admit if I'm wrong 👌
- ·3.2.Many nervous souls here which makes the stock fall. Waiting for the market day February 5 with news and possible investors who will pull the stock in the right direction. See enormous potential here👍🚀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
35
Myynti
Määrä
1 517
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 | - | - | ||
| 3 | - | - | ||
| 1 | - | - | ||
| 1 | - | - | ||
| 1 | - | - |
Ylin
6,56VWAP
Alin
6,315VaihtoMäärä
3,5 539 615
VWAP
Ylin
6,56Alin
6,315VaihtoMäärä
3,5 539 615
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
2025 Q3 -tulosraportti
Vain PDF
78 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·15 t sittenI am completely convinced that we will see 5:- before Q1 is over, unfortunately.·11 t sittenI bet against and say that we will touch 8 kr before Q1 ends - based on readout of CU/ EAP 🤞🏽·9 t sittenI hope you are right, but my assessment is that we might see price levels around 5 kr before data is presented. Uncertainty is high and there is clear selling pressure from actors who want to exit their positions regardless of price, which continues to push the price down. After the data is released, it is impossible to predict the outcome. If the result is positive, I can definitely see levels around 8 kr or higher, but until then, the price is driven more by sentiment than fundamentals. It is also noticeable in forums and Discord that many are trying to support each other, but unfortunately, the price development has been negative for a longer period, which is frustrating for all investors, including myself. I still hope that the company delivers strong data going forward and that the trend turns in the long run.
- ·8.2.Advancement for Cereno Scientific and candidate CS1 The Expanded Access Program (EAP) has now concluded after the last patient completed their last visit. This provides the company with access to valuable long-term data that complements the promising signals of "reverse vascular remodeling" observed in phase IIa. The insights from the EAP will now pave the way for the next major development step: a global phase IIb study with planned recruitment start in Q2 2026. 💬 – Reaching last patient last visit in the EAP is an important milestone, says CEO Sten R. Sörensen.
- ·5.2.Very good KMD today from management. The future looks bright, I am convinced of that. The only question is how long the market will delay reflecting the value in the share price. For those who are long-term, this will definitely pay off over time. Now we are just over +5 %, but if you know Cereno, you know that it often swings quickly and one should not be surprised if we are down again short-term. At the same time, that doesn't fundamentally change the case. The company continues to deliver, and sooner or later fundamentals usually catch up with the valuation.·6.2.They value Cereno at 6.6 billion at the start of Phase 2b. The market for PAH is far from as large as, for example, for oncological studies which are valued in the same range. As Sten says, we hope that if all goes well, we will have a product on the market in 5-6 years. When Merck acquired winrevair, Sotatercept was in Phase 3. But yes, I have shares, will hold the shares all the way, but that we are approaching 21 SEK per share this year, I have great doubts about. But I'll be the first to admit if I'm wrong 👌
- ·3.2.Many nervous souls here which makes the stock fall. Waiting for the market day February 5 with news and possible investors who will pull the stock in the right direction. See enormous potential here👍🚀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
35
Myynti
Määrä
1 517
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 | - | - | ||
| 3 | - | - | ||
| 1 | - | - | ||
| 1 | - | - | ||
| 1 | - | - |
Ylin
6,56VWAP
Alin
6,315VaihtoMäärä
3,5 539 615
VWAP
Ylin
6,56Alin
6,315VaihtoMäärä
3,5 539 615
Välittäjätilasto
Dataa ei löytynyt